About PredictImmune
PredictImmune is a company based in Cambridge (United Kingdom) founded in 2017.. PredictImmune has raised $18.32 million across 3 funding rounds from investors including University of Cambridge, Parkwalk and BGF. The company has 15 employees as of March 31, 2021. PredictImmune operates in a competitive market with competitors including ArcherDX, BioLife Solutions, Qiagen, Devyser and RoosterBio, among others.
- Headquarter Cambridge, United Kingdom
- Employees 15 as on 31 Mar, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Predictimmune Limited
- Date of Incorporation 13 Jan, 2017
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
$107.44 K (USD)22as on Mar 31, 2022
-
Net Profit
$-2.28 M (USD)38as on Mar 31, 2022
-
EBITDA
$-3.2 M (USD)27as on Mar 31, 2022
-
Total Equity Funding
$18.32 M (USD)
in 3 rounds
-
Latest Funding Round
$12.25 M (USD), Series B
Jul 30, 2019
-
Investors
University of Cambridge
& 5 more
-
Employee Count
15
as on Mar 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of PredictImmune
PredictImmune has successfully raised a total of $18.32M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12.25 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $12.2M
-
First Round
First Round
(01 May 2017)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2019 | Amount | Series B - PredictImmune | Valuation | Parkwalk , BGF | |
| Apr, 2018 | Amount | Grant - PredictImmune | Valuation |
investors |
|
| May, 2017 | Amount | Series A - PredictImmune | Valuation | Parkwalk |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in PredictImmune
PredictImmune has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include University of Cambridge, Parkwalk and BGF. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech companies are invested in by Parkwalk venture capital firm.
|
Founded Year | Domain | Location | |
|
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by PredictImmune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PredictImmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Predictimmune Comparisons
Competitors of PredictImmune
PredictImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, BioLife Solutions, Qiagen, Devyser and RoosterBio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| domain | founded_year | HQ Location |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| domain | founded_year | HQ Location |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
|
| domain | founded_year | HQ Location |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| domain | founded_year | HQ Location |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Predictimmune
Frequently Asked Questions about PredictImmune
When was PredictImmune founded?
PredictImmune was founded in 2017.
Where is PredictImmune located?
PredictImmune is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Is PredictImmune a funded company?
PredictImmune is a funded company, having raised a total of $18.32M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.08M, raised on May 01, 2017.
How many employees does PredictImmune have?
As of Mar 31, 2021, the latest employee count at PredictImmune is 15.
What is the annual revenue of PredictImmune?
Annual revenue of PredictImmune is $107.44K as on Mar 31, 2022.
What does PredictImmune do?
PredictImmune was founded in 2017 and is based in Cambridge, United Kingdom. Operations focus on the diagnostics sector within biotechnology, where prognostic tools are developed to support treatment decisions for immune-mediated inflammatory diseases. The initial product, PredictSURE IBD, is used to stratify patients with inflammatory bowel disease, including Crohns disease and ulcerative colitis, to inform clinical outcomes.
Who are the top competitors of PredictImmune?
PredictImmune's top competitors include Qiagen, ArcherDX and RoosterBio.
Who are PredictImmune's investors?
PredictImmune has 6 investors. Key investors include University of Cambridge, Parkwalk, BGF, Cambridge Innovation Capital, and Wellcome.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.